Pre-Conference Seminar Day
Tuesday 19th March 2024
8:15am Check-In & Coffee + Light Breakfast
9:15 am Welcoming Remarks from the IgA Nephropathy Foundation
9:25 am Chair’s Opening Remarks
9:30 am Exploring the Options for Novel Target Candidates Based on Susceptibility Loci Identified Through GWAS
Synopsis
- Overview of the genetic architecture of IgA nephropathy
- Genetic insights into the pathogenic signaling pathways in IgA nephropathy
- Genetic drivers of IgA production and their relationship to IgA nephropathy
- Using genetic findings to identify novel drug targets for IgA nephropathy
10:00 am Unravelling the Epidemiological Factors Associated with IgA Nephropathy to Shoot for Targets of Greatest Unmet Need
Synopsis
- Exploring geographic and environmental variabilities that result in more aggressive phenotypes
- Understanding how the epidemiology of IgA feeds into target identification and validation
- Leveraging variation in prevalence, severity and treatment response among different subpopulations of IgA to uncover subtype-specific targets
10:30am Morning Break & Refreshments
11:00 am Panel Discussion | Novel Targets in Development for IgA Nephropathy: Where are the Current Late Phase Trials Heading?
Synopsis
- From complement to APRIL to ETA: what targets are currently in development and looking most promising?
- Exploring new treatment possibilities with combinational targeting
- Exploring the current thinking on IgA pathogenesis to direct priorities for future target development
11:45 am Deciphering the Precise Role of Complement Activation in IgA Nephropathy to Develop Therapeutic Inhibitors
Synopsis
- Discussing the role of the complement cascade in the pathogenesis of IgA nephropathy
- Review results of the Phase II trial of RO7434656, an antisense oligonucleotide targeting complement
- Providing an overview of the Phase III IMAgINATION trial of RO7434656 in patients with IgA nephropathy
12:15 Lunch & Networking
1:15 pm Highlighting the Potential Role of BlyS & APRIL in the Pathogenesis of IgA Nephropathy
Synopsis
- Discussing the plausible role of both BlyS and APRIL in the pathogenesis of IgA nephropathy
- Discussing the rationale for combined inhibition of these cytokines in the treatment of IgA nephropathy
- Reviewing phase 2b data on atacicept in the treatment of IgA nephropathy and the design of the ORIGIN3 study
1:45 pm Rational for Targeting APRIL in IgA Nephropathy
Synopsis
- Providing an overview of the Sibeprenlimab development program
- Reviewing the latest data from the phase 2 trial
- Optimizing trial design for the phase 3 program: The Visionary Trial Design
2:15 pm Comparative Global Analysis of IgAN Patients’ Real-World Experiences: Mapping the Patient Pathway in Diverse Nations
Synopsis
- Evaluating disease severity, symptom burden, and treatment satisfaction assessments from both IgAN patients and nephrologists
- Outlining the real-world comparison study methodology and global data gathering process
- Emphasizing significant findings and the resulting implications derived from the study
2:45 pm Panel Discussion | Evaluating the Evolving Treatment Landscape for IgA Nephropathy: What Happens Next as More & More Therapies Emerge?
Synopsis
- As more approvals emerge within the IgAN landscape, how will the evolving standard of care make showing efficacy on top of these other therapies harder?
- It may require multiple therapies with distinct MOAs to optimally treat the patient with IgAN; how can industry best help enhance further knowledge about the efficacy and safety of potential combination therapeutic regimens?
- Determining which drug is best for which subset of IgAN patients: where do all the current therapies fit into the current standard of care management, and can we use observed differences in responses to match drugs to specific patient populations?
- Encouraging more effective engagement of patients in treatment and trial decision making